Broncho‐Vaxom(R) (OM‐85 BV) soluble components stimulate sinonasal innate immunity

Broncho‐Vaxom® (OM‐85 BV) soluble components stimulate sinonasal innate immunity
Vasiliki Triantafillou BS  Alan D. Workman MD  Neil N. Patel BA, BS  Ivy W. Maina BA Charles C. L. Tong MD  Edward C. Kuan MD, MBA  David W. Kennedy MD  … See all authors
First published: 07 January 2019 https://doi.org/10.1002/alr.22276
Funding sources for the study: National Institutes of Health (National Institute on Deafness and Other Communication Disorders [NIDCD] R01DC013588 to N.A.C.); Veterans Affairs Merit Review (CX001617 to N.A.C.).
Potential conflict of interest: None provided.
Presented orally at the ARS Meeting at the annual Combined Otolaryngology Spring Meetings (COSM) on April 18‐22, 2018, National Harbor, MD.
Read the full text
PDFTOOLS SHARE
Abstract
Background
Broncho‐Vaxom® (OM‐85 BV) is an extract of infectious respiratory bacteria that is used as an immunostimulant outside of the United States for the prevention and treatment of bronchitis and rhinosinusitis. Prior studies have shown that use of OM‐85 BV is associated with reduction in frequency of respiratory infection and decreased duration of antibiotic usage. However, the effects of OM‐85 BV on respiratory mucosal innate immunity are unknown.

Methods
Human sinonasal epithelial cells were grown at an air‐liquid interface (ALI). Ciliary beat frequency (CBF) and nitric oxide (NO) production in response to stimulation with OM‐85 BV was measured in vitro. Pharmacologic inhibitors of bitter taste receptor (T2R) signaling were used to determine if this pathway was taste‐receptor–mediated.

Results
Apical application of OM‐85 BV resulted in an NO‐mediated increase in CBF (p < 0.05) and increased NO production (p < 0.0001) when compared to saline‐stimulated control cultures. ALI pretreatment with taste receptor pathway inhibitors blocked OM‐85 BV–induced increases in NO.

Conclusion
OM‐85 BV has ciliostimulatory and immunogenic properties that may be partially responsible for its observed efficacy as a respiratory therapeutic. These responses were NO‐dependent and consistent with T2R activation. Further work is necessary to elucidate specific component‐receptor signaling relationships.
https://onlinelibrary.wiley.com/doi/10.1002/alr.22276